Los Angeles, CA, June 17, 2007 --(PR.com
)-- Gamma Medica-Ideas (GM-I) announced today the addition of a new High Resolution CT subsystem to the company’s FLEX Triumph™ Pre-clinical Imaging Platform that produces striking improvements in CT imaging. The new CT subsystem contains a variable focal spot x-ray source which provides the user with the option to select between high resolution (≤ 15 microns) or low-dose (≤ 1.2 cGy), high throughput (< 1 minute) whole body mouse scans.
GM-I will offer the High Resolution CT subsystem as an option in its multi-modality FLEX Triumph™ Platform, which also supports X-PET™, LabPET™, X-SPECT® (NaI or CZT), and X-O™ (CT) pre-clinical imaging sub-systems. FLEX Triumph can be configured in single, dual, or tri-modality combinations. The new subsystem is also available as an upgrade to GM-I’s existing FLEX™ customers.
“This new subsystem will be invaluable to our customers, as it will allow them to accomplish any MicroCT study, such as advanced pre-clinical bone analysis, where spatial resolution is a significant factor” said Dr. Bradley E. Patt, GM-I’s President and Chief Executive Officer. “An added benefit is that users now will have the flexibility of performing scans with high spatial resolution at low power, without sacrificing the option of performing high speed scans with the same x-ray tube.”
GM-I's first delivery of their new subsystem will be in the second quarter of 2007 to Case Western Reserve University. "We look forward to utilizing the high resolution CT system for many applications: from imaging and analyzing minute changes in the trabecular micro-architecture in bone related to disease states such as arthritis and osteoporosis, to identifying new bone formation after stem cell transplant, all will be enabled by Gamma Medica's new high-resolution CT," states Zhenghong Lee, Ph.D., Assistant Professor, Case Center for Imaging Research at Case Western Reserve University in Cleveland, Ohio.
About Gamma Medica-Ideas, Inc.
Gamma Medica-Ideas (GM-I) designs, builds and services imaging systems based on novel technologies to improve patient health through early diagnosis of disease, improved patient treatment and by enabling new drug discovery. GM-I is dedicated to leading medical imaging into a new digital era with its unique sensor readout systems. The company’s core digital imaging technologies also hold great promise for a new class of solutions for the safety and security markets. In the pre-clinical space, GM-I’s FLEX TriumphTM imaging platform is marketed for medical research and drug development. The Triumph system combines PET (X-PETTM or its new fully digital LabPETTM), SPECT (X-SPECT®) and CT (X-OTM) modalities in the world’s first tri-modality system. In the clinical space, GM-I offers LumaGEM®, its dual-headed Molecular Breast Imaging (MBI) based system for early diagnosis and treatment of breast cancer. The digital gamma imaging technology in LumaGEM offers significant advances in resolution and contrast which have allowed for identification of millimeter sized breast cancers missed by mammography, especially in women with dense breast tissue.